{"id":"larotaxel-rpr109881-xrp9881","safety":{"commonSideEffects":[{"rate":null,"effect":"Neutropenia"},{"rate":null,"effect":"Peripheral neuropathy"},{"rate":null,"effect":"Anemia"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Nausea/vomiting"},{"rate":null,"effect":"Alopecia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"As a third-generation taxane derivative, larotaxel stabilizes microtubules by binding to β-tubulin, similar to paclitaxel and docetaxel but with improved pharmacokinetic properties and potentially reduced peripheral neuropathy. This mechanism disrupts mitotic spindle formation, causing G2/M phase arrest and triggering apoptosis in rapidly dividing cancer cells. The drug was designed to have better tissue penetration and lower neurotoxicity compared to earlier taxanes.","oneSentence":"Larotaxel is a microtubule-stabilizing taxane that binds to β-tubulin and prevents microtubule depolymerization, leading to cell cycle arrest and apoptosis in cancer cells.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:49:14.007Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic breast cancer"},{"name":"Non-small cell lung cancer"},{"name":"Gastric cancer"}]},"trialDetails":[{"nctId":"NCT00087958","phase":"PHASE2","title":"Intravenous RPR109881 in Male or Female Patients With Advanced Breast Cancer Who no Longer Respond to Anthracycline, Taxane and Capecitabine Treatment","status":"COMPLETED","sponsor":"Sanofi","startDate":"2004-08","conditions":"Breast Cancer","enrollment":168},{"nctId":"NCT00081796","phase":"PHASE3","title":"Breast Cancer Trial of RPR109881 Versus Capecitabine in Male or Female Patients With Advanced Breast Cancer","status":"COMPLETED","sponsor":"Sanofi","startDate":"2004-04","conditions":"Breast Cancer, Metastases","enrollment":438}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"larotaxel (RPR109881, XRP9881)","genericName":"larotaxel (RPR109881, XRP9881)","companyName":"Sanofi","companyId":"sanofi","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Larotaxel is a microtubule-stabilizing taxane that binds to β-tubulin and prevents microtubule depolymerization, leading to cell cycle arrest and apoptosis in cancer cells. Used for Metastatic breast cancer, Non-small cell lung cancer, Gastric cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}